Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
9 "Jina Yun"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Special Article
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim
Cancer Res Treat. 2024;56(3):721-742.   Published online November 29, 2023
DOI: https://doi.org/10.4143/crt.2023.1043
AbstractAbstract PDFPubReaderePub
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
  • 5,364 View
  • 305 Download
Close layer
Erratum
ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim
Cancer Res Treat. 2023;55(3):1061-1061.   Published online April 21, 2023
DOI: https://doi.org/10.4143/crt.2021.1115.E
Corrects: Cancer Res Treat 2022;54(1):1
PDFPubReaderePub
  • 2,747 View
  • 109 Download
Close layer
Special Article
Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim
Cancer Res Treat. 2022;54(1):1-9.   Published online December 13, 2021
DOI: https://doi.org/10.4143/crt.2021.1115
Correction in: Cancer Res Treat 2023;55(3):1061
AbstractAbstract PDFPubReaderePub
Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Citations

Citations to this article as recorded by  
  • Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
    Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeo
    Scientific Reports.2025;[Epub]     CrossRef
  • Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology
    Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin L
    Journal of Cancer Research and Practice.2024;[Epub]     CrossRef
  • Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II
    Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Youn
    BMC Cancer.2024;[Epub]     CrossRef
  • Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
    I. Vanni, L. Pastorino, V. Andreotti, D. Comandini, G. Fornarini, M. Grassi, A. Puccini, E. T. Tanda, A. Pastorino, V. Martelli, L. Mastracci, F. Grillo, F. Cabiddu, A. Guadagno, S. Coco, E. Allavena, F. Barbero, W. Bruno, B. Dalmasso, S. E. Bellomo, C. M
    Journal of Translational Medicine.2024;[Epub]     CrossRef
  • Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Journal of Pathology and Translational Medicine.2024; 58(4): 147.     CrossRef
  • Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
    Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
    Cancer Research and Treatment.2024; 56(3): 721.     CrossRef
  • Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
    T.-Y. Kim, S.Y. Kim, J.H. Kim, H.A. Jung, Y.J. Choi, I.G. Hwang, Y. Cha, G.-W. Lee, Y.-G. Lee, T.M. Kim, S.-H. Lee, S. Lee, H. Yun, Y.L. Choi, S. Yoon, S.W. Han, T.-Y. Kim, T.W. Kim, D.Y. Zang, J.H. Kang
    ESMO Open.2024; 9(10): 103709.     CrossRef
  • Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
    Yongjun Cha, Sheehyun Kim, Sae-Won Han
    Cancer Research and Treatment.2023; 55(2): 367.     CrossRef
  • Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis
    Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
    International Journal of Cancer.2023; 153(3): 571.     CrossRef
  • Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
    Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
    Journal of Pathology and Translational Medicine.2023; 57(5): 265.     CrossRef
  • Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
    Gianpiero Fasola, Maria C. Barducci, Valeria D. Tozzi, Luigi Cavanna, Saverio Cinieri, Francesco Perrone, Carmine Pinto, Antonio Russo, Anna Sapino, Francesco Grossi, Giuseppe Aprile
    JCO Precision Oncology.2023;[Epub]     CrossRef
  • Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients
    Yuji SHIMODA, Takeshi NAGASHIMA, Kenichi URAKAMI, Fukumi KAMADA, Sou NAKATANI, Maki MIZUGUCHI, Masakuni SERIZAWA, Keiichi HATAKEYAMA, Keiichi OHSHIMA, Tohru MOCHIZUKI, Sumiko OHNAMI, Shumpei OHNAMI, Takeshi KAWAKAMI, Kentaro YAMAZAKI, Haruyasu MURAKAMI, H
    Biomedical Research.2022; 43(4): 115.     CrossRef
  • Clinical Implication of Molecular Tumor Board
    Soohyeon Lee
    The Korean Journal of Medicine.2022; 97(5): 319.     CrossRef
  • Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study
    Jung Ho Park, Mi Jung Kwon, Jinwon Seo, Ho Young Kim, Soo Kee Min, Lee Su Kim
    Journal of Breast Cancer.2022; 25(5): 379.     CrossRef
  • 10,157 View
  • 529 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
Original Article
Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
Cancer Res Treat. 2020;52(1):277-283.   Published online July 12, 2019
DOI: https://doi.org/10.4143/crt.2019.292
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by  
  • Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
    Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
    The Oncologist.2025;[Epub]     CrossRef
  • From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
    Zesi Liu, Chunli Jing, Fandou Kong
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • SOX17 expression in ovarian clear cell carcinoma
    Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
    Journal of Ovarian Research.2024;[Epub]     CrossRef
  • Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
    Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
    Clinical and Experimental Obstetrics & Gynecology.2024;[Epub]     CrossRef
  • Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
    Li Shuqing, Zhu Zhiling
    Cancer Medicine.2023; 12(6): 6668.     CrossRef
  • Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
    Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
    Current Medical Research and Opinion.2023; 39(6): 901.     CrossRef
  • The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
    Yuan Zhuang, Hua Yang
    Cancer Control.2023;[Epub]     CrossRef
  • Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
    Satoe Fujiwara
    Japanese Journal of Clinical Oncology.2023; 53(8): 664.     CrossRef
  • Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
    Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
    Journal of Gynecologic Oncology.2023;[Epub]     CrossRef
  • Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
    Yang Gao, Wei Ding, Pengpeng Qu
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • A clearer view on ovarian clear cell carcinoma
    Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
    Acta Clinica Belgica.2022; 77(4): 792.     CrossRef
  • Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
    Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
    Archives of Gynecology and Obstetrics.2022; 305(5): 1279.     CrossRef
  • Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
    Peng Chen, Chi-Yuan Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
    Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
    Medicine.2022; 101(37): e30666.     CrossRef
  • Clear cell carcinoma of the ovary: a clinical and molecular perspective
    Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
    International Journal of Gynecological Cancer.2021; 31(4): 605.     CrossRef
  • Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
    Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
    BMC Cancer.2021;[Epub]     CrossRef
  • The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
    Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
    Journal of Surgery and Medicine.2021; 5(8): 1.     CrossRef
  • Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
    Qian Chen, Shu Wang, Jing-He Lang
    Journal of Ovarian Research.2020;[Epub]     CrossRef
  • 8,982 View
  • 421 Download
  • 22 Web of Science
  • 18 Crossref
Close layer
Case Report
A Case Report of Paraneoplastic Pemphigus Associated with Esophageal Squamous Cell Carcinoma
Jin Hyun Cho, Nam Jun Kim, Sung Min Ko, Chunghun Kim, Hee Kyung Ahn, Jina Yun, Yeon Hee Park
Cancer Res Treat. 2013;45(1):70-73.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.70
AbstractAbstract PDFPubReaderePub
Paraneoplastic pemphigus is an autoimmune blistering and erosive mucocutaneous syndrome associated with underlying neoplasm. It is primarily associated with lymphoproliferative disorders, and uncommonly with malignancies of epithelial origin. We report on a case of a 68-year-old male who presented with whole body bullous and erosive skin lesions. Findings on upper gastrointestinal endoscopy and skin biopsy revealed esophageal squamous cell carcinoma and paraneoplastic pemphigus. Palliative chemotherapy and systemic glucocorticoid were started, however, the patient died of overwhelming sepsis on the ninth day of chemotherapy. This case demonstrates that paraneoplastic pemphigus can occur in esophageal squamous cell carcinoma and could be a cause of morbidity.

Citations

Citations to this article as recorded by  
  • Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology
    Hannah J. Anderson, Simo Huang, Jason B. Lee
    Journal of the American Academy of Dermatology.2024; 91(1): 1.     CrossRef
  • T cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen
    Hayato Takahashi, Hisato Iriki, Yasuhiko Asahina
    The Journal of Dermatology.2023; 50(2): 112.     CrossRef
  • S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)
    Emiliano Antiga, Rikke Bech, Roberto Maglie, Giovanni Genovese, Luca Borradori, Barbara Bockle, Marzia Caproni, Frédéric Caux, Nisha Suyien Chandran, Alberto Corrà, Francesco D'Amore, Maryam Daneshpazhooh, Dipankar De, Dario Didona, Marian Dmochowski, Kos
    Journal of the European Academy of Dermatology and Venereology.2023; 37(6): 1118.     CrossRef
  • A Case of Severe Refractory Pemphigus Vulgaris in a Patient With Stable Esophageal Malignancy
    Vanessa C Browne, Catherine Choi, Eugenio M Capitle, Reena Khianey
    Cureus.2021;[Epub]     CrossRef
  • Paraneoplastic pemphigus and cutaneous squamous cell carcinoma: uncommun 3 cases
    Afaf Khouna
    Journal of Dermatology & Cosmetology.2021; 5(1): 17.     CrossRef
  • Pemphigus Vulgaris and Bullous Pemphigoid of the Upper Aerodigestive Tract: A Review Article and Novel Approaches to Management
    Mohammed Hassan Hussain, Faiz Tanweer, Georgios Sakagiannis, Manish Mair, Sara Mahmood, Sithamparappillai Ashokkumar
    ORL.2021; 83(6): 395.     CrossRef
  • A rare association of paraneoplastic pemphigus with gastric signet cell ring carcinoma
    Anfisa Lepekhova, Olga Olisova, Natalia Teplyuk, Dmitrii Zolotenkov, Anastasiia Allenova
    Australasian Journal of Dermatology.2019;[Epub]     CrossRef
  • Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus
    Kyle T. Amber, Manuel Valdebran, Sergei A. Grando
    Autoimmunity Reviews.2018; 17(10): 1002.     CrossRef
  • Pemphigus
    Patricia Chirinos-Saldaña, Alejandro Navas, Arturo Ramírez-Miranda, María Carmen Jiménez-Martínez, Enrique O. Graue-Hernández
    Eye & Contact Lens: Science & Clinical Practice.2016; 42(2): 91.     CrossRef
  • 136,949 View
  • 83 Download
  • 9 Crossref
Close layer
Original Articles
Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases
Ji Yeon Kwon, Jina Yun, Han Jo Kim, Kyoung-Ha Kim, Se-Hyung Kim, Sang-Cheol Lee, Hyun Jung Kim, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(4):244-249.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.244
AbstractAbstract PDFPubReaderePub
PURPOSE
The prognosis of gastric cancer patients with bone marrow metastases is extremely poor. The current study was conducted to evaluate the clinical outcomes of advanced gastric cancer patients with bone marrow metastases.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 26 advanced gastric cancer patients with bone marrow metastases who were treated at Soonchunhyang University Hospital between September 1986 and February 2009.
RESULTS
The median age was 46 years (range, 24 to 61 years). All patients had poorly differentiated adenocarcinoma, including 17 signet ring cell carcinomas. The majority of the patients had thrombocytopenia, anemia, and elevated lactate dehydrogenase levels. Sixteen patients (61.5%) received palliative chemotherapy (median, 4 cycles; range, 1 to 13 cycles). The median overall survival after detection of bone marrow metastases for the cohort of patients was 37 days (95% confidence interval, 12.5 to 61.5 days). The median overall survival after detection of bone marrow involvement was 11 days in the best supportive care group (range, 2 to 34 days) and 121 days (range, 3 to 383 days) in the palliative chemotherapy group (p<0.001). The causes of death were tumor progression (11 patients, 45%), brain hemorrhage (6 patients, 25%), infection (5 patients, 21%), and disseminated intravascular coagulation (1 patient, 4%). There were no chemotherapy-related deaths.
CONCLUSION
Palliative chemotherapy could be considered in advanced gastric cancer patients with bone marrow metastases as a treatment option.

Citations

Citations to this article as recorded by  
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Comprehensive review of solid tumor bone marrow metastasis
    Lanxin Zhang, Fengxi Chen, Lingzhi Xu, Ning Li, Qiping Zhuo, Yijin Guo, Xueqing Wang, Meijie Wen, Zuowei Zhao, Man Li
    Critical Reviews in Oncology/Hematology.2024; 194: 104248.     CrossRef
  • Mechanism and clinical progression of solid tumors bone marrow metastasis
    Ruohan Yang, Lin Jia, Jiuwei Cui
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Is Bone Marrow Metastasis in Gastric Cancer Adequate for Best Supportive Care Decisions? Or is There Still a Chance?
    Berkan Karabuğa, Ergin Aydemir, Fatih Yıldız, Necati Alkış
    Acta Haematologica Oncologica Turcica.2024;[Epub]     CrossRef
  • Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
    Wen Ye, Liping He, Lei Su, Zhousan Zheng, Meilin Ding, Sheng Ye
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Bone Metastasis From Gastric Adenocarcinoma—What Are the Risk Factors and Associated Survival? A Large Comprehensive Population-Based Cohort Study
    Lei Huang, Yajie Zhao, Yan Shi, Weiguo Hu, Jun Zhang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Gastric Cancer With Multiple Bone Metastases: An Uncommon Primary Presentation
    João Barbosa-Martins, Salomé Marques, Olinda Miranda, Bárbara Lima, Jorge Cotter
    Cureus.2022;[Epub]     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • The influence of serum sodium concentration on prognosis in patients with urothelial carcinoma treated by radical cystectomy
    Yan Zhang, Zuojun Wang, Xue Yang, Qingchun Zhao, Long He
    Medicine.2022; 101(52): e31973.     CrossRef
  • Access to Palliative Care Services and Clinical Outcomes of Patients With Solid Malignancy-Associated Myelophthisis in a Resource-Limited Setting
    Cesar Vargas-Serafin, Aldo A. Acosta-Medina, Kevin Teran-De-la-Sancha, Jesus Delgado-de-la-Mora, María T. Bourlon, Christianne Bourlon
    American Journal of Hospice and Palliative Medicine®.2021; 38(8): 932.     CrossRef
  • Disseminated Bone Marrow Carcinomatosis Due to Malignant Melanoma of Unknown Primary Origin
    Kotaro Matsumoto, Kentaro Kikuchi, Tomohiro Kikuyama, Go Saito, Takako Adachi, Ayako Watanabe, Hiromichi Tsunashima, Takayuki Tsujikawa, Ken Sato, Shinpei Doi
    Internal Medicine.2021; 60(21): 3469.     CrossRef
  • Survival Outcomes and Treatment Decision by Human Papillomavirus Status Among Patients With Stage IVC Head and Neck Squamous Cell Carcinoma
    Ping Zhou, Yi-Feng Yu, Chen-Lu Lian, Jun Wang, Ren-Gong Zhuo, San-Gang Wu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Gastric Signet Ring Cell Carcinoma with Metastasis to the Bone and Bone Marrow in a Patient with 12-Year-Disease-Free Interval and Unusually Long Survival Time
    Hyung Woo Kim, Mi Jin Gu, Jong Ho Lee
    Laboratory Medicine Online.2021; 11(4): 305.     CrossRef
  • Signet-ring cells in the bone marrow as an indication of cryptic metastasis of breast carcinoma
    Shuang Ma, Bruce D. Leckey Jr, Wan-Lin Zhang, Hong-Tao Xu, Lian-He Yang, Endi Wang
    Medicine.2019; 98(11): e14883.     CrossRef
  • Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
    Giovanni Fucà, Luigi Mariani, Salvatore Lo Vullo, Giulia Galli, Rossana Berardi, Massimo Di Nicola, Claudio Vernieri, Daniele Morelli, Katia Dotti, Ilaria Fiordoliva, Silvia Rinaldi, Cecilia Gavazzi, Filippo Pietrantonio, Marco Platania, Filippo de Braud
    Scientific Reports.2019;[Epub]     CrossRef
  • Malignant Pleural Mesothelioma with Bone Marrow Metastases
    Hiroaki Ihara, Norihiro Harada, Naoko Shimada, Koichiro Kanamori, Takuo Hayashi, Toshimasa Uekusa, Kazuhisa Takahashi
    Internal Medicine.2018; 57(17): 2541.     CrossRef
  • An unusual hematological presentation of gastric adenocarcinoma
    Hendra Koncoro, Eddy Setijoso, Findy Prasetiawaty, Maisie ME Johan, Renaningtyas Tambun
    Gastroenterology & Hepatology: Open Access.2018;[Epub]     CrossRef
  • Clinical outcome of 30 patients with bone marrow metastases
    Min Hang Zhou, Zhi Hong Wang, Hong Wei Zhou, Mo Liu, Yong Jian Gu, Jun Zhong Sun
    Journal of Cancer Research and Therapeutics.2018; 14(Suppl 2): S512.     CrossRef
  • Recurrent gastric cancer metastasizing to the bone marrow: A case report of a rare presentation
    Ernest Fonocho, Nail Aydin, Srini Reddy, Subhasis Misra
    International Journal of Surgery Case Reports.2017; 37: 165.     CrossRef
  • Clinical Outcomes of Endoscopic Hemostasis for Bleeding in Patients with Unresectable Advanced Gastric Cancer
    In Ji Song, Hyun Ju Kim, Ji Ae Lee, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Hyunsoo Chung
    Journal of Gastric Cancer.2017; 17(4): 374.     CrossRef
  • Generalized high bone mineral density on bone density scanning: a case of gastric carcinoma with bone metastasis
    Pianpian Fan, Qin Wang, Chunyan Lu, Decai Chen
    Postgraduate Medicine.2017; 129(2): 299.     CrossRef
  • A case of disseminated carcinomatosis of the bone marrow originating from gastric cancer 3 years after intraperitoneal chemotherapy against peritoneal carcinomatosis
    Takayuki Okuno, Hironori Yamaguchi, Joji Kitayama, Hironori Ishigami, Takeshi Nishikawa, Junichiro Tanaka, Toshiaki Tanaka, Tomomichi Kiyomatsu, Keisuke Hata, Hiroaki Nozawa, Kazushige Kawai, Shinsuke Kazama, Soichiro Ishihara, Eiji Sunami, Toshiaki Watan
    World Journal of Surgical Oncology.2016;[Epub]     CrossRef
  • Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy
    Yoshinobu Seki, Kunihiko Wakaki
    International Journal of Hematology.2016; 104(4): 506.     CrossRef
  • Endoscopic Management of Tumor Bleeding from Inoperable Gastric Cancer
    Young-Il Kim, Il Ju Choi
    Clinical Endoscopy.2015; 48(2): 121.     CrossRef
  • An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation
    Harjot Kaur, Appalanaidu Sasapu, Jeanette Ramos, Rangaswamy Govindarajan
    Journal of Gastrointestinal Cancer.2015; 46(4): 413.     CrossRef
  • Development and Validation of a Prognostic Score to Predict Survival in Adult Patients With Solid Tumors and Bone Marrow Metastases
    Wen-Chi Chou, Kun-Yun Yeh, Meng-Ting Peng, Jen-Shi Chen, Hung-Ming Wang, Yung-Chang Lin, Chien-Ting Liu, Shau-Hsuan Li, Pei-Hung Chang, Cheng-Hsu Wang, Ping-Tsung Chen, Yu-Shin Hung, Chang-Hsien Lu
    Medicine.2015; 94(23): e966.     CrossRef
  • Her-2 Positive Gastric Cancer Presented with Thrombocytopenia and Skin Involvement: A Case Report
    Deniz Arslan, Mukremin Uysal, Ali Murat Tatlı, Seyda Gunduz, Sema Sezgin Goksu, Cumhur İbrahim Başsorgun, Hasan Senol Coskun, Hakan Bozcuk, Burhan Savaş
    Case Reports in Oncological Medicine.2014; 2014: 1.     CrossRef
  • Gastric Carcinoma with Bone Marrow Metastasis: A Case Series
    Ahmet Şiyar Ekinci, Öznur Bal, Tahsin Özatlı, İbrahim Türker, Onur Eşbah, Ayşe Demirci, Burçin Budakoğlu, Ülkü Yalçıntaş Arslan, Emrah Eraslan, Berna Öksüzoğlu
    Journal of Gastric Cancer.2014; 14(1): 54.     CrossRef
  • Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis
    Yu Jung Kim, Se Hyun Kim, Jin Won Kim, Jeong-Ok Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
    European Journal of Cancer.2014; 50(16): 2810.     CrossRef
  • Methylated TIMP-3 DNA in Body Fluids Is an Independent Prognostic Factor for Gastric Cancer
    Jiang-Liu Yu, Ping Lv, Jing Han, Xin Zhu, Lian-Lian Hong, Wang-Yu Zhu, Xin-Bao Wang, Yi-Chen Wu, Pei Li, Zhi-Qiang Ling
    Archives of Pathology & Laboratory Medicine.2014; 138(11): 1466.     CrossRef
  • Prognostic Factors in Adult Patients with Solid Cancers and Bone Marrow Metastases
    Yu-Shin Hung, Wen-Chi Chou, Tai-Di Chen, Tse-Ching Chen, Po-Nan Wang, Hung Chang, Hung-Chih Hsu, Wen-Chi Shen, Wei-Hong Cheng, Jen-Shi Chen
    Asian Pacific Journal of Cancer Prevention.2014; 15(1): 61.     CrossRef
  • Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer†
    Yumi Tanaka, Tatsuya Yoshimasu, Shoji Oura, Yoshimitsu Hirai, Mitsumasa Kawago, Masako Ikeda, Yoshitaka Okamura
    European Journal of Cardio-Thoracic Surgery.2013; 44(3): 539.     CrossRef
  • 12,919 View
  • 105 Download
  • 32 Crossref
Close layer
Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer
Han Jo Kim, Jun Young Eun, Young Woo Jeon, Jina Yun, Kyoung Ha Kim, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(3):154-159.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.154
AbstractAbstract PDFPubReaderePub
PURPOSE
We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer.
MATERIALS AND METHODS
Between January 2006 and August 2009, 39 patients with histologically-confirmed, metastatic or recurrent gastric cancer underwent chemotherapy, and the results were retrospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks.
RESULTS
Thirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete response and 11 patients achieved a partial response (response rate, 28.2%). The median time-to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic toxicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported.
CONCLUSION
This study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer.

Citations

Citations to this article as recorded by  
  • Post-Marketing Surveillance of a generic Oxaliplatin (AlvoxalⓇ) in Iranian Patients with Cancer
    Farhad Shahi, Mojtaba Gorji, Mehrdad Payandeh, Hamid Rezvani, Mohammad Vaezi, Sharareh Seifi, Alireza Baari, Reza Khalili-Dizaji, Seyed Mehdi Hashemi, Saeid Salimi, Hosein Kamranzadeh, Babak Shazad, Sina Salari, Davoud Oulad Dameshghi, Mehdi Sarkheil, Meh
    Current Therapeutic Research.2022; 96: 100657.     CrossRef
  • Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity
    Linlin Yang, Hua Wang, Wanting Lu, Gangqi Yang, Zian Lin, Ruibing Chen, Hongyan Li
    Journal of Proteomics.2022; 266: 104682.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer
    H Liu, J Lu, Y Hua, P Zhang, Z Liang, L Ruan, C Lian, H Shi, K Chen, Z Tu
    Cell Death & Disease.2015; 6(1): e1595.     CrossRef
  • Oxaliplatin induced-neuropathy in digestive tumors
    María Sereno, Gerardo Gutiérrez-Gutiérrez, César Gómez-Raposo, Miriam López-Gómez, Maria Merino-Salvador, Francisco Zambrana Tébar, Cristina Rodriguez-Antona, Enrique Casado
    Critical Reviews in Oncology/Hematology.2014; 89(1): 166.     CrossRef
  • Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity ofBCL-2family gene members in stomach cancer cells
    Dimitra Florou, Christos Patsis, Alexandros Ardavanis, Andreas Scorilas
    Cancer Biology & Therapy.2013; 14(7): 587.     CrossRef
  • The kallikrein-related peptidase 13 (KLK13) gene is substantially up-regulated after exposure of gastric cancer cells to antineoplastic agents
    Dimitra Florou, Konstantinos Mavridis, Andreas Scorilas
    Tumor Biology.2012; 33(6): 2069.     CrossRef
  • 10,598 View
  • 59 Download
  • 7 Crossref
Close layer
Phase II Clinical Trial of Genexol(R) (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
Han Jo Kim, Kyoung Ha Kim, Jina Yun, Se Hyung Kim, Hyun Jung Kim, Sang-Cheol Lee, Sang Byung Bae, Chan Kyu Kim, Nam Su Lee, Kyu Taek Lee, Do-Jin Kim, Seong-Kyu Park, Jong-Ho Won, Dae Sik Hong, Hee Sook Park
Cancer Res Treat. 2011;43(1):19-23.   Published online March 31, 2011
DOI: https://doi.org/10.4143/crt.2011.43.1.19
AbstractAbstract PDFPubReaderePub
PURPOSE
This phase II clinical trial was conducted to evaluate the activity and safety of a combination treatment of paclitaxel (Genexol(R)) plus carboplatin in patients with advanced non-small cell lung cancer.
MATERIALS AND METHODS
Chemotherapy-naive patients having histologically confirmed advanced or metastatic non-small cell lung cancer were enrolled. Genexol(R) was administered at 225 mg/m2 intravenous (IV) infusion over 3 hours, followed by carboplatin (area under the concentration-time curve=6) IV on day 1 every 3 weeks.
RESULTS
Twenty-eight patients were enrolled between January 2003 and January 2005. A total of 110 cycles of chemotherapy were given. The median number of chemotherapy cycles was 4. A total of 25 study patients were evaluable. On an intent-to-treat basis, there were ten partial responses (response rate 35.7%). The median time-to-progression was 3.2 months (95% confidence interval [CI], 1.5 to 4.9) and the median overall survival was 8.2 months (95% CI, 4.1 to 12.3). The main hematologic grade 3/4 toxicity was neutropenia, which was observed in 14 (50.0%) patients. The main non-hematologic toxicity was peripheral neuropathy, which was observed in 12 patients (42.9%). Grade 3/4 neuropathy occurred in 8 patients (28.6%) and three patients discontinued treatment because of neuropathy.
CONCLUSION
In this trial, the combination of Genexol(R) and carboplatin showed significant activity as first line treatment for patients with advanced or metastatic non-small cell lung cancer. However, a modest dose reduction of Genexol(R) is needed due to sensory neuropathy.

Citations

Citations to this article as recorded by  
  • Therapeutic Nanoparticles: Advantages and Toxicity
    Dr. Lata Ramrakhiani
    Indian Journal of Environment Engineering.2022; 2(1): 19.     CrossRef
  • Engineering Chimeric Receptors To Investigate the Size- and Rigidity-Dependent Interaction of PEGylated Nanoparticles with Cells
    Wei-Chiao Huang, Pierre-Alain Burnouf, Yu-Cheng Su, Bing-Mae Chen, Kuo-Hsiang Chuang, Chia-Wei Lee, Pei-Kuen Wei, Tian-Lu Cheng, Steve R. Roffler
    ACS Nano.2016; 10(1): 648.     CrossRef
  • Nanotechnology applications in thoracic surgery
    Sophie C. Hofferberth, Mark W. Grinstaff, Yolonda L. Colson
    European Journal of Cardio-Thoracic Surgery.2016; 50(1): 6.     CrossRef
  • Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
    Nazila Kamaly, Basit Yameen, Jun Wu, Omid C. Farokhzad
    Chemical Reviews.2016; 116(4): 2602.     CrossRef
  • Novel Water-Borne Polyurethane Nanomicelles for Cancer Chemotherapy: Higher Efficiency of Folate Receptors Than TRAIL Receptors in a Cancerous Balb/C Mouse Model
    Elham Ajorlou, Ahmad Yari Khosroushahi, Hamid Yeganeh
    Pharmaceutical Research.2016; 33(6): 1426.     CrossRef
  • Reinvention of chemotherapy
    Tu Nguyen-Ngoc, Eric Raymond
    Current Opinion in Oncology.2015; 27(3): 232.     CrossRef
  • Lung Cancer Nanomedicine: Potentials and Pitfalls
    Deniz Ali Bölükbas, Silke Meiners
    Nanomedicine.2015; 10(21): 3203.     CrossRef
  • Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
    Susana Patricia Egusquiaguirre, Manuela Igartua, Rosa María Hernández, José Luis Pedraz
    Clinical and Translational Oncology.2012; 14(2): 83.     CrossRef
  • Novel water-soluble polyurethane nanomicelles for cancer chemotherapy: physicochemical characterization and cellular activities
    Ahmad Yari Khosroushahi, Hossein Naderi-Manesh, Hamid Yeganeh, Jaleh Barar, Yadollah Omidi
    Journal of Nanobiotechnology.2012;[Epub]     CrossRef
  • Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
    Twan Lammers, Fabian Kiessling, Wim E. Hennink, Gert Storm
    Journal of Controlled Release.2012; 161(2): 175.     CrossRef
  • 11,006 View
  • 68 Download
  • 10 Crossref
Close layer
Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2010;42(2):101-106.   Published online June 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.2.101
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy.

Materials and Methods

A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei.

Results

Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%).

Conclusion

In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.

Citations

Citations to this article as recorded by  
  • Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
    Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
    APMIS.2017; 125(2): 79.     CrossRef
  • Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine
    Shalong Wang, Lianwen Yuan
    BioScience Trends.2016; 10(3): 171.     CrossRef
  • Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
    Tumor Biology.2014; 35(4): 2941.     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
    Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 921.     CrossRef
  • ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women
    Seung‐Su HAN, Jae Weon KIM, Sang Hoon LEE, Dong Ho KIM, Noh‐Hyun PARK, Yong‐Sang SONG, Soon‐Beom KANG
    Asia-Pacific Journal of Clinical Oncology.2012;[Epub]     CrossRef
  • Gastric Cancer
    Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta
    Current Problems in Cancer.2011; 35(3): 97.     CrossRef
  • 10,119 View
  • 42 Download
  • 8 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP